酪氨酸激酶抑制剂在HER2阳性乳腺癌中应用的可视化分析

邹婧; 楚尧娟; 杜秋争; 岳鹤影; 王小宝; 杜书章

doi:10.6039/j.issn.1001-0408.2023.24.14

您当前的位置：

首页 >

文章列表页 >

酪氨酸激酶抑制剂在HER2阳性乳腺癌中应用的可视化分析

药物与临床 | 更新时间：2023-12-22

- 酪氨酸激酶抑制剂在HER2阳性乳腺癌中应用的可视化分析
- Visual analysis of tyrosine kinase inhibitors in HER2 positive breast cancer
- 中国药房 2023年34卷第24期页码：3036-3041
- 作者机构：
  
  郑州大学第一附属医院药学部，郑州　450052
- 作者简介：
  
  药师，硕士研究生。研究方向：临床药理学。E-mail：zoujing309@163.com
  主任药师，硕士生导师。研究方向：循证医学、药物经济学。E-mail：dushuzhang911@163.com
- 基金信息：
  
  河南省重点研发与推广专项(232102311200)
- DOI：10.6039/j.issn.1001-0408.2023.24.14
  中图分类号： R979.1;R737.9
- 纸质出版日期：2023-12-30，
  
  收稿日期：2023-07-17，
  
  修回日期：2023-11-17，
扫描看全文
邹婧,楚尧娟,杜秋争等.酪氨酸激酶抑制剂在HER2阳性乳腺癌中应用的可视化分析 ^Δ[J].中国药房,2023,34(24):3036-3041.

ZOU Jing,CHU Yaojuan,DU Qiuzheng,et al.Visual analysis of tyrosine kinase inhibitors in HER2 positive breast cancer[J].ZHONGGUO YAOFANG,2023,34(24):3036-3041.
邹婧,楚尧娟,杜秋争等.酪氨酸激酶抑制剂在HER2阳性乳腺癌中应用的可视化分析 ^Δ[J].中国药房,2023,34(24):3036-3041. DOI： 10.6039/j.issn.1001-0408.2023.24.14.

ZOU Jing,CHU Yaojuan,DU Qiuzheng,et al.Visual analysis of tyrosine kinase inhibitors in HER2 positive breast cancer[J].ZHONGGUO YAOFANG,2023,34(24):3036-3041. DOI： 10.6039/j.issn.1001-0408.2023.24.14.

摘要

目的

分析酪氨酸激酶抑制剂（TKIs）治疗人表皮生长因子受体2（HER2）阳性乳腺癌的研究现状、热点和发展趋势。

方法

在Web of Science核心合集数据库中检索TKIs治疗HER2阳性乳腺癌的相关文献，使用CiteSpace 6.1.R3软件对发文作者、国家/地区、机构、学科领域、期刊、关键词进行可视化分析。

结果

共纳入732篇文献，发文量呈逐年上升趋势，以美国发文最多（中心度0.10），我国发文量排第2位（中心度0.05）。发文量和被引频次最多的作者分别是澳大利亚圣文森特大学医院的Crown和美国加州大学洛杉矶分校的Slamon；发文量最多的机构是美国得克萨斯大学安德森癌症中心，最多的期刊是美国

Journal of Clinical Oncology

；研究热点主要集中在HER2阳性乳腺癌治疗药物、TKIs作用受体、TKIs作用机制、HER2阳性乳腺癌脑转移、TKIs临床研究5个方面；前沿领域和发展趋势主要为TKIs与其他药物或治疗手段联用以增强靶向性并降低毒副作用。

结论

TKIs治疗HER2阳性乳腺癌的研究受到国内外学者的重视。我国学者和研究团队未来需要加强合作交流，可从TKIs单用及联合用药治疗HER2阳性乳腺癌的疗效及安全性方面加强与其他国家的合作。

Abstract

OBJECTIVE

To analyze the research status， hotspot and development trend of tyrosine kinase inhibitors （TKIs） in the treatment of human epidermal growth factor receptor 2 （HER2） positive breast cancer.

METHODS

The literature related to TKIs in the treatment of HER2 positive breast cancer were searched from the Web of Science core collection database； the author， country/region， institution， subject field， journal and keywords was visualized by CiteSpace 6.1.R3 software.

RESULTS

A total of 732 pieces of literature were included， and the number of literature published showed an increasing trend year by year. The number of literature published in the United States was the largest （center degree 0.10）， and the number of literature published in China ranked second （center degree 0.05）. The most published and cited authors were Crown from St. Vincent’s University Hospital in Australia and Slamon from University of California， Los Angeles in the United States； the institution with the highest number of literature was the University of Texas MD Anderson Cancer Center， and the journal with the highest number of literature was

the Journal of Clinical Oncology

. The research mainly focused on five aspects： HER2 positive breast cancer treatment drugs， TKIs receptor， TKIs mechanism of action， HER2 positive breast cancer brain metastasis， and TKIs clinical trials. The main frontier areas and development trends were the combination of TKIs with other drugs or therapies to enhance targeting and reduce toxic side effects.

CONCLUSIONS

The study of TKIs in the treatment of HER2 positive breast cancer has attracted the attention of scholars at home and abroad. Chinese scholars and research teams need to strengthen cooperation and communication in the future， and cooperation with other countries should be strengthened in terms of the efficacy and safety of TKIs alone and combined with other drugs in the treatment of HER2 positive breast cancer.

关键词

酪氨酸激酶抑制剂人表皮生长因子受体-2阳性乳腺癌可视化分析

Keywords

human epidermal growth factor receptor-2 positive breast cancervisual analysis

references

CHOONG G M，CULLEN G D，O’SULLIVAN C C. Evolving standards of care and new challenges in the ma-nagement of HER2-positive breast cancer[J]. CA Cancer J Clin，2020，70（5）：355-374.

CAO W，CHEN H D，YU Y W，et al. Changing profiles of cancer burden worldwide and in China：a secondary analysis of the global cancer statistics 2020[J]. Chin Med J，2021，134（7）：783-791.

DESANTIS C E，MA J M，GAUDET M M，et al. Breast cancer statistics[J]. CA Cancer J Clin，2019，69（6）：438-451.

ROY V，PEREZ E A. Beyond trastuzumab：small mole-cule tyrosine kinase inhibitors in HER-2-positive breast cancer[J]. Oncologist，2009，14（11）：1061-1069．

CURIGLIANO G，MUELLER V，BORGES V，et al.Tucatinib vs placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases（HER2CLIMB）：final overall survival analysis[J]. Ann Oncol，2022，33（3）：321-329.

GEYER C E，FORSTER J，LINDQUIST D，et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer[J]. N Engl J Med，2006，355（26）：2733-2743.

NAHTA R，YUAN L X，ZHANG B，et al. Insulin-like growth factor-Ⅰ receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells[J]. Cancer Res，2005，65（23）：11118-11128.

CHEN Y，CHEN C M，LIU Z Y，et al. Methodological features of CiteSpace knowledge maps [J]. Sci Res，2015，33（2）：242-253.

ZENG Y，YU D L，TIAN W T，et al. Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer[J]. Curr Opin Oncol，2022，34（1）：54-65.

ZHUANG X L，WANG Z，FAN J S，et al. Structure-guided and phage-assisted evolution of a therapeutic anti-EGFR antibody to reverse acquired resistance[J]. Nat Commun，2022，13（1）：4431.

BAI X，SUN P Y，WANG X H，et al. Structure and dynamics of the EGFR/HER2 heterodimer[J]. Cell Discov，2023，9（1）：18.

CORTÉS J，FUMOLEAU P，BIANCHI G V，et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab：activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer[J]. J Clin Oncol，2012，30（14）：1594-1600.

CORTI C，ANTONARELLI G，CRISCITIELLO C，et al. Targeting brain metastases in breast cancer[J]. Cancer Treat Rev，2022，103：102324.

BAILLEUX C，EBERST L，BACHELOT T. Treatment strategies for breast cancer brain metastases[J]. Br J Cancer，2021，124（1）：142-155.

PARSAI S，MILLER J A，JULOORI A，et al. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases[J]. J Neurosurg，2019，132（2）：503-511.

MORIKAWA A，STANCHINA E D，PENTSOVA E，et al. Phase Ⅰ study of intermittent high-dose lapatinib alterna-ting with capecitabine for HER2-positive breast cancer patients with central nervous system metastases[J]. Clin Cancer Res，2019，25（13）：3784-3792.

HURVITZ S，SINGH R，ADAMS B，et al. Phase Ⅰb/Ⅱ single-arm trial evaluating the combination of everolimus，lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases（TRIO-US B-09）[J]. Ther Adv Med Oncol，2018，10：1758835918807339.

MACPHERSON I R，SPILIOPOULOU P，RAFII S，et al. A phase Ⅰ/Ⅱ study of epertinib plus trastuzumab with or without chemotherapy in patients with HER2-positive metastatic breast cancer[J]. Breast Cancer Res，2019，22（1）：1.

BRUFSKY A，ZULFIQAR M，PEGUERO J，et al. Abstract PD1-07：a phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy[J]. Cancer Res，2021，81：PD1-7.

ZHANG J，MCANDREW N，YU W L，et al. Abstract P2-13-43：preclinical and early clinical safety and pharmacokinetics data of DZD1516，an BBB-penetrant selective HER2 inhibitor for the treatment of HER2 positive metastatic breast cancer[J]. Cancer Res，2022，82：P2-13.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

2013－2023年中医药治疗溃疡性结肠炎的文献计量学分析

人工智能应用于医院药学服务领域的文献计量学分析

基于CiteSpace可视化分析复发高级别胶质瘤的治疗研究现状

基于Web of Science的非酒精性脂肪肝病治疗研究可视化分析

我国中成药临床综合评价研究热点与趋势分析